Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
Chuang YangTiantian XuanQing GongXin DaiChengjun WangRongyu ZhangWen ZhaoJian WangWeiming YueJisheng LiPublished in: Thoracic cancer (2024)
PD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-naïve ES-SCLC patients. Benmelstobart plus anlotinib with chemotherapy (CT) yielded better survival benefit versus CT alone or other ICIs + CT with caution for more adverse effects along with the addition of an antiangiogenic agent.
Keyphrases
- image quality
- small cell lung cancer
- dual energy
- computed tomography
- contrast enhanced
- end stage renal disease
- newly diagnosed
- ejection fraction
- positron emission tomography
- locally advanced
- chronic kidney disease
- peritoneal dialysis
- magnetic resonance imaging
- prognostic factors
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- rectal cancer
- replacement therapy
- pet ct